BioMarin Pharmaceutical company profile
Company profile
BioMarin Pharmaceutical has 3,221 employees and is headquartered in San Rafael, United States.
The company's activity centres on rare-disease therapies, with a portfolio built around enzyme replacement treatments and peptide-based medicines. Its marketed products include VIMIZIM for mucopolysaccharidosis type IV A, VOXZOGO for achondroplasia, NAGLAZYME and ALDURAZYME for other MPS disorders, PALYNZIQ for lowering blood phenylalanine, BRINEURA for Batten disease type 2, and KUVAN for phenylketonuria. Two candidates in development, BMN 333, a longer-acting CNP, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy, extend the pipeline. Its buyers include hospitals, specialty pharmacies, distributors and wholesalers, as well as non-U.S. government agencies, and sales reach the US, Europe, Latin America, the Middle East and Asia Pacific.
In the fiscal year ended December 2025, revenue reached USD 3.2 billion, up 12.9% from the previous year, and net income came to USD 348.9 million. The company has 3,221 employees. Founded in 1996, it is headquartered in San Rafael, California.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 770 Lindaro Street, 94901, San Rafael
- Employees
- 3,221
- Chief executive
- Alexander Hardy
- Founded
- 1996
- Fiscal year
- January - December
- Listing
- BMRN · NASDAQ
- Currency
- USD
- ISIN
- US09061G1013
- Website
- biomarin.com
BioMarin Pharmaceutical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| Halozyme TherapeuticsHALO | United States | $14.67B | 423 | 56.8% | 38.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
